Fierce Biotech13h
Eli Lilly helps struggling Sangamo with $1.4B gene therapy deal
Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...
Fierce Biotech18h
Cell therapy biotech Neurona nabs $102M to push epilepsy candidate into phase 3
Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.
Fierce Biotech22h
Aldeyra’s dry eye drug suffers second FDA rejection, but imminent data spur hope of fast recovery
The FDA has set back Aldeyra Therapeutics’ ambitions to win approval for its dry eye disease, rejecting its second ...
Fierce Biotech23h
BeiGene abandons ociperlimab over poor phase 3 prospects in latest blow to TIGITs
BeiGene is scrapping ociperlimab over a disappointing phase 3 outlook two years after Novartis handed back the anti-TIGIT ...
Fierce Biotech22h
Roche shows most Alzheimer's patients below amyloid threshold after 28 weeks
Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...
Fierce Biotech20h
Siemens AG to acquire lab R&D platform Dotmatics for $5.1B
Siemens AG—and that’s Siemens Siemens, not Siemens Healthineers—is expanding its industrial software business further into ...